Agilon Health (AGL) shares fell nearly 33% in Friday premarket activity, a day after reporting a wider Q3 net loss and missing market expectations.

The company reported a Q3 net loss from continuing operations late Thursday of $0.29 per share, widening from a loss of $0.06 a year earlier.

Analysts polled by Capital IQ expected a GAAP loss of $0.11.

Total revenue for the quarter ended Sept. 30 was $1.45 billion, up from $1.14 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.47 billion.

For Q4, the company expects total revenue of $1.51 billion to $1.53 billion. Analysts polled by Capital IQ expect $1.48 billion.

For 2024, Agilon now expects total revenue of $6.05 billion to $6.07 billion, compared with $6.01 billion to $6.04 billion previously. Analysts surveyed by Capital IQ expect $6.05 billion.